Pacific Biosciences of California, Inc.
PACB· Nasdaq
PACBPacific Biosciences of California, Inc.
Released Aug 2, 2023, after the close
10-Q filed Aug 4, 2023, 35 days after period end · 0001299130-23-000098
| Metric | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|
| Revenue | $47.57M | $35.47M | $30.61M | $19.08M |
| Net Income | -$69.83M | -$71.39M | -$41.00M | -$23.09M |
| EPS Diluted |
Pacific Biosciences of California, Inc. · CIK 1299130 · Engraved from SEC EDGAR
| -$0.28 |
| -$0.32 |
| -$0.21 |
| -$0.15 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
